Clinical trial
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986 · Southeastern Gynecologic Oncology, Other · Completed
Key facts
| NCT number | NCT00466986 |
|---|---|
| Title | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer |
| Official title | A Phase II, Non-Randomized Study of Abraxane Plus Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Southeastern Gynecologic Oncology, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Abraxane |
| Enrollment | 40 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Oct 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: